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Abstract
Background: Making misoprostol widely available for management of postpartum haemorrhage (PPH) and post
abortion care (PAC) is essential for reducing maternal mortality. Private pharmacies (thereafter called “pharmacies”)
are integral in supplying medications to the general public in Senegal. In the case of misoprostol, pharmacies are
also the main supplier to public providers and therefore have a key role in increasing its availability. This study seeks
to understand knowledge and provision of misoprostol among pharmacy workers in Dakar, Senegal.
Methods: A cross-sectional survey was conducted in Dakar, Senegal. 110 pharmacy workers were interviewed face-to-
face to collect information on their knowledge and practice relating to the provision of misoprostol.
Results: There are low levels of knowledge about misoprostol uses, registration status, treatment regimens and side
effects among pharmacy workers, and corresponding low levels of training on its uses for reproductive health. Provision
of misoprostol was low; of the 72% (n = 79) of pharmacy workers who had heard of the product, 35% (n = 27) reported
selling it, though rarely for reproductive health indications. Almost half (49%, n = 25) of the respondents who did not
sell misoprostol expressed willingness to do so. The main reasons pharmacy workers gave for not selling the product
included stock outs (due to product unavailability from the supplier), perceived lack of demand and unwillingness to
stock an abortifacient.
Conclusions: Knowledge and availability of misoprostol in pharmacies in Senegal is low, posing potential challenges for
delivery of post-abortion care and obstetric care. Training is required to address low levels of knowledge of misoprostol
registration and uses among pharmacy workers. Barriers that prevent pharmacy workers from stocking misoprostol,
including weaknesses in the supply chain and stigmatisation of the product must be addressed. Low reported sales for
reproductive health indications also suggest limited prescribing of the product by health providers. Further research is
needed to explore the reasons for this barrier to misoprostol availability.
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Background
Senegal has made progress toward reducing maternal
mortality over the past two decades. However, with a
maternal mortality ratio (MMR) estimated at 315 per
100,000 live births in 2015 [1], Senegal was not able to
meet its Millennium Development Goal target of 190 by
2015 [2], and further advances are needed. While little
data exists on the causes of maternal deaths in Senegal,
post-partum haemorrhage is responsible for an esti-
mated 34% of maternal deaths in sub-Saharan Africa [3].
Globally, a large proportion of deaths in early pregnancy
are also due to unsafe abortion [4, 5]. It has been dem-
onstrated that making misoprostol readily available in
low-resource settings for management of postpartum
haemorrhage (PPH) and post abortion care (PAC) can
have a significant impact on reducing maternal deaths
[6, 7]. Misoprostol is particularly appropriate for low
resource settings as it does not require refrigeration and
can be administered at the community-level by auxiliary
midwives [8, 9].
Misoprostol was included in the World Health
Organization’s Essential Medicines List (EML) in 2005
and was named for management of incomplete abor-
tion and miscarriage in 2009 and for the prevention
of PPH and induction of labour in 2011 [10–12]. In
2013, misoprostol was registered on the EML in
Senegal as an anti-haemorrhagic and hemostatic prod-
uct, and is available on the market for the treatment
of duodenal and gastric ulcers, prevention of non-
steroidal anti-inflammatory drugs (NSAID)-induced
peptic ulcers, the prevention and treatment of PPH,
PAC, intra-uterine foetal death (IUFD), and ripening
of the cervix. The EML has yet to be widely dissemi-
nated in Senegal. Several brands of misoprostol exist
on the market today, one of which, Misoclear®, is reg-
istered for gynaecological indications such as PPH
and PAC. Recent research on misoprostol provision at
the community level for PPH and PAC in Senegal has
shown high levels of efficacy and acceptability [13, 14] and
found it to be more cost effective for PPH prevention than
oxytocin [15]. However, misoprostol remains underused
[13, 14], and its availability in public and private health
facilities is limited [16].
Misoprostol is also an abortifacient. Abortion is legal
in Senegal only to save the mother’s life [17]. Evidence
suggests that women recourse to unsafe procedures out-
side the health system when attempting to terminate
pregnancies for other reasons [18], contributing to
Senegal’s high rates of maternal morbidity and mortality
[1, 19]. In some restrictive settings around the world, it
has been documented that women are using misoprostol
purchased over the counter as a safer alternative to high
risk methods of pregnancy termination such as those
undertaken by untrained providers in unhygienic settings
[20, 21]. Awareness of misoprostol’s use for termination of
pregnancy among providers and pharmacy workers is not
documented in Senegal.
Global evidence indicates that private pharmacies
(thereafter called “pharmacies”) and pharmacy workers
are often the first and sometimes only point of contact
with the health system and therefore play an important
role in providing basic health information and services,
including misoprostol, in many countries [22–27]. Phar-
macies may be chosen because of their long opening
hours, short waiting times, convenient locations, ano-
nymity, and because they offer greater availability of
medicines than public health facilities [26]. Despite this
potential, there are concerns about the quality of care
provided by pharmacies; pharmacy curricular may not
include courses on the role of pharmacists as commu-
nity health advisors and frontline staff may not be for-
mally trained on medications, regimen and doses [26].
In Senegal, a University awarded diploma in pharmacy is
a required to open and run a pharmacy, but not to sell
medications from the outlet. Availability of misoprostol
from pharmacies is also a concern, as pharmacists may
be unwilling to stock and dispense a medication that can
be used as an abortifacient [27].
Pharmacies are integral to the supply of medications
in Senegal; selling misoprostol both to the general public
and to providers. In 2014, the government opened a ten-
der to purchase misoprostol for the public sector; how-
ever, at the time of writing, public providers were mostly
accessing the product through pharmacies. To enable
continued reductions in MMR in Senegal, it is important
to ensure that misoprostol is widely available in pharma-
cies. This study seeks to understand knowledge and
provision of misoprostol among pharmacies in Dakar,
Senegal. Specifically, its objectives are (i) to document
knowledge of misoprostol among pharmacy workers; (ii)
to document the availability of and demand for miso-
prostol in the pharmacies; and (iii) to document self-
reported provision practices by pharmacy workers.
Methods
In September 2013, Marie Stopes International and the
Population Council conducted a cross-sectional survey
with pharmacy workers in Dakar, Senegal [18]. We
obtained the list of all 557 registered pharmacies in the
Dakar region (Dakar city and three suburbs located
between 15 and 30 km from Dakar city centre) from the
Order of Pharmacists, and used simple random sampling
to select 110 pharmacies for inclusion in the study.
Endorsement for the study was given by the Order of
Pharmacists who contacted pharmacy workers in writing
prior to data collection to endorse the study. Within
each pharmacy, one worker was selected for a face-to-
face interview. Selection criteria were (i) being involved
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in selling/distributing medicine; and (ii) being over
18 years of age. In each pharmacy, the owner or man-
ager was approached first, and if they did not meet the
eligibility criteria, for example if they did not directly sell
or distribute medicine, the next most senior and eligible
staff member was invited to participate. Pharmacy
workers received an information sheet explaining the
study, and were asked to give informed consent prior to
interview. Interviewers were trained to explain the
importance of the study and to ensure participants
understood that their responses would be anonymised.
Interviews took place in a setting within the pharmacy
where the interview could not be overheard and where
the interviewee felt comfortable providing information.
A standardised, structured questionnaire was adminis-
tered by a trained interviewer. The questionnaire col-
lected information on pharmacy characteristics, staff
background, knowledge and current practice relating to
misoprostol as well as current frequency of misoprostol
sales. Participants were able to refer to sales registers
where needed. The questionnaire also included open-
ended “Other” categories for some questions to collect
answers not pre-coded, and respondents were given the
opportunity to provide additional comments at the end
of the interview. The instrument was pre-tested in eight
pharmacies in Dakar.
Data were entered into an access database using Epi
Info. Double data entry was used to check for data entry
errors. Quantitative data were analysed descriptively
using Stata 13 (StataCorp LP, College Station, TX, USA).
Results
One hundred and ten structured interviews were com-
pleted, a response rate of 100%. Table 1 shows that
about half (49%, n = 54) of respondents worked in phar-
macies in Dakar city, and half (51%, n = 56) in pharma-
cies in the suburbs. The mean age of respondents was
41, and 63% (n = 69) of them were male. While overall,
82% (n = 89) had a relevant degree from a (public) uni-
versity or private institution, data show heterogeneity in
training by location: all respondents in Dakar city had
some level of professional or university training whereas
36% (n = 20) of pharmacy workers in the suburbs had
only received on-the-job training.
Knowledge and training of pharmacy workers
Table 2 shows that a high proportion of respondents had
heard of misoprostol (72%, n = 79). Gastric and duo-
denal ulcer was the condition for which knowledge of
registration and use of the product were highest. There
was little awareness that misoprostol was registered for
PPH prevention (1%, n = 1) and treatment (3%, n = 2),
PAC (13%, n = 10), and other conditions. Knowledge of
misoprostol’s reproductive health uses was highest for
termination of pregnancy (38%, n = 30) and PAC (13%,
n = 10), and lowest for conditions such as prevention
(1%, n = 1) and treatment (4%, n = 3) of PPH, treatment
of IUFD (1%, n = 1) and cervical ripening (3%, n = 2).
Knowledge that misoprostol could be used for a condi-
tion did not translate into knowledge of the regimen.
For example, 31% (n = 18) of the respondents who knew
misoprostol could be used to treat gastric and duodenal
ulcer reported that they did not know the regimen.
Furthermore, 60% (n = 6) of those who knew misopros-
tol could be used for PAC reported not knowing its regi-
men and only 20% (n = 2) gave the correct total dose
and route of administration (600mcg administered orally
or 400mcg administered sublingually). Additionally,
almost half of respondents that had heard of misoprostol
could not name a side effect (Table 2).
Table 1 Characteristics of respondents
Dakar city Suburbsa Total
N % N % N %
Total 54 49 56 51 110 100
Gender
Male 31 57 38 68 69 63
Female 23 43 18 32 41 37
Ageb
22-30 11 21 7 13 18 17
31-40 12 23 28 53 40 38
41-50 18 34 14 26 32 30
51-65 12 23 4 8 16 15
Education
Primary 0 0 1 2 1 1
Secondary 20 37 24 43 44 40
University degree 34 63 31 55 65 59
Size of pharmacy staffc
2-3 13 25 23 42 36 33
4-6 32 60 27 49 59 55
7+ 8 15 5 9 13 12
Position held
Owner 24 44 22 39 46 42
Manager 5 9 10 18 15 14
Employee 25 46 23 41 48 44
Trainee 0 0 1 2 1 1
Training leveld
On the job training 0 0 20 36 20 18
Private institution 20 37 8 15 28 26
(Public) University degree 34 63 27 49 61 56
aSuburbs regroup pharmacies in the districts of Pikine, Guédiawaye and
Rufisqu bData missing for one pharmacy worker in Dakar and three pharmacy
workers in the Suburbs cData missing for one pharmacy worker in Dakar, one
pharmacy worker in the Suburbs didn’t know the number of staff dData
missing for one pharmacy worker in the Suburbs
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For misoprostol to be used effectively, it should be
stored away from heat and moisture, but the majority
of respondents were only aware of the need to keep
misoprostol protected from heat (misoprostol in
Senegal is packaged in moisture resistant blister pack-
aging, however it is still recommended practice to min-
imise exposure to humidity).
While the majority of respondents that had heard of
misoprostol reported ever receiving information or
training on misoprostol, the predominant source of
information was literature or brochures (45%, n = 22)
(Table 3). Other sources of information on misoprostol
included colleagues (20%, n = 10) and medical represen-
tatives or pharmaceutical companies (22%, n = 11). Just
10% (n = 5) of respondents indicated receiving informa-
tion or training on misoprostol from a University. A low
proportion of pharmacy workers had received training
on post abortion care (12%, n = 6), while no respondents
had received information about misoprostol use to pre-
vent or treat PPH, cervical ripening or IUFD. Over two-
thirds (67%, n = 33) had received information regarding
the treatment of duodenal or gastric ulcer. 86% (n = 67)
of respondents wanted more support or information
about misoprostol, and 51% (n = 40) reported they do
not feel confident providing misoprostol to end users.
Among respondents desiring more information, the
most commonly requested topics were the uses of miso-
prostol (37%, n = 25), its side effects (30%, n = 20) and
dosage (28%, n = 19). However, 58% (n = 39) of respon-
dents wanted training on all aspects of misoprostol.
Provision of misoprostol and reasons for not selling it
Table 4 shows that of the 79 respondents who had heard
of misoprostol, 27 (35%) reported selling it. They sold
misoprostol most commonly to men (56%, n = 15), mar-
ried women (56%, n = 15) and unmarried women (41%,
n = 11). No respondents reported selling misoprostol to
Table 2 Pharmacy worker knowledge of misoprostol
Number Percent
Respondent had heard of misoprostol 79 72
Knowledge of conditions Used for Registered for
N % N %
Duodenal or gastric ulcer 59 75 48 61
Prophylaxis of NSAID-induced peptic ulcers 5 6 4 5
Prevention of PPH 1 1 1 1
Treatment of PPH 3 4 2 3
PAC 10 13 10 13
Treatment for intrauterine fetal death (IUFD) 1 1 0 0
Cervical ripening 2 3 1 1
Termination of pregnancy 30 38 5 6
Knowledge of storage instructions N %
Store away from heat 66 84
Store away from moisture 22 28
Knowledge of side effects









Table 3 Training and training needs on misoprostol among
pharmacy workers who had heard of the drug
Number Percent








Television or Internet 2 4
Conditions trained in
Duodenal or gastric ulcer 33 67
Prophylaxis of NSAID-induced peptic ulcers 3 6
Prevention or treatment of PPH 0 0
PAC 6 12
Treatment IUFD 0 0
Cervical ripening 0 0
Respondent reported they do not feel confident
providing misoprostol to end usersa, b
40 51




Uses of misoprostol 25 37
Storage of misoprostol 2 3
Dosage 19 28
Method of administration 5 7
Side effects 20 30
Complications 14 21
All aspects 39 58
aAmong those respondents who had heard of misoprostol bData missing from
one pharmacy worker
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adolescents. 30% (n = 8) of respondents reported selling
misoprostol to health providers, most commonly to doc-
tors (19%, n = 5) and midwives (7%, n = 3) (not shown).
Sales were overwhelmingly reported to be for duodenal
or gastric ulcer (63%, n = 17). Sale for reproductive
health care uses was rarely mentioned.
Just under half (49%, n = 25) of the 51 respondents
who had heard of but didn’t sell misoprostol expressed
interest in and willingness to stock the product. The
most common reasons for not stocking misoprostol
were lack of demand (56%, n = 30), unavailability of the
product (46%, n = 24) and unwillingness to stock aborti-
facients (42%, n = 23).
Demand for misoprostol
Whether they sold misoprostol or not, pharmacy
workers reported having received requests for informa-
tion about and/or purchase of the product. For example,
15% (n = 12) of study respondents who had heard of
misoprostol reported receiving requests from health pro-
fessionals for information about the product. The major-
ity of the 12 (75%, n = 9) reported receiving requests
from midwives. Providers most commonly wanted to
know misoprostol’s indications (58%, n = 7) and its side
effects (42%, n = 5).
Among the 27 pharmacy workers who reported selling
misoprostol, 22% (n = 6) reported receiving requests to
purchase misoprostol over the counter, i.e. without a
prescription. No pharmacy worker reported selling it
without prescription. Over the counter requests had
been received for treatment of gastric ulcer (three
respondents) and to terminate pregnancy (one respond-
ent). Three respondents reported receiving clients who
did not specify the indication.
Among the 52 respondents who said that they did not
sell misoprostol, 21% (n = 11) reported experiencing a
demand for the product from health professionals, and
71% (n = 37) reported demand from end users. A small
number (8%, n = 3) said that the demand was for ter-
mination of pregnancy. However, the majority (62%,
n = 23) reported not asking the indication for which
clients wanted misoprostol.
Discussion
This study found low levels of knowledge about miso-
prostol use, registration status, treatment regimens and
side effects among pharmacy workers in Dakar, Senegal.
Similar findings have recently been reported in Tanzania
and Nigeria [28–30]. Although the majority of pharmacy
workers had received some form of information or train-
ing on misoprostol, it was often only in the form of litera-
ture or brochures, and only on the treatment of duodenal
or gastric ulcer. Pharmacy workers expressed high levels
of desire for information or support on misoprostol.
As expected, given low levels of knowledge, the pro-
portion of pharmacy workers stocking and providing
misoprostol was also low, and very few respondents
reported selling the product for reproductive health uses.
However, half of the respondents who reported that they
were not currently selling misoprostol said they were
willing to stock it; their reasons for not selling the
medicine were concerns about stock outs and perceived
lack of demand. Recently, steps taken in Senegal to
strengthen the supply chain have been successful in pre-
venting stock outs of contraceptives [22]. Such efforts
should also be applied to misoprostol.
Globally there is a critical shortage of highly-skilled
healthcare workers such as physicians, nurses and mid-
wives [31]. Expanding the role of pharmacists is recom-
mended as one strategy for facilitating increased access
to medications and reducing pressure on other areas of
the health system [32, 33]. Pharmacists also have a vital
role in assuring the effectiveness of medications and can
prevent harm from incorrect use [32, 33]. As the scope
and complexity of the pharmacist’s role increases, their
competencies and skills need to be kept up-to-date
Table 4 Self-reported provision of misoprostol among 27
pharmacy workers
Number Percent
Pharmacies sell misoprostola 27 35
Brands sold Price per box [95%CI] (West
African CFA Franc)
Cytotec (60 x 200mcg doses/box) 16,376
[13,824; 18,927]
Misoclear (10 x 200mcg doses/box) 2162
[2149; 2176]
Arthotec (30 x 200mcg doses/box) 5701
[5369; 6032]
Clients misoprostol sold to N %
Health care providers 8 30
Married women 15 56
Unmarried women 11 41
Adolescents 0 0
Men 15 56
Conditions misoprostol sold for N %
Duodenal or gastric ulcer 17 63
Prophylaxis of NSAID-induced peptic ulcers 2 7
Prevention or treatment of PPH 0 0
Post abortion care 1 4
Treatment for intrauterine fetal death (IUFD) 0 0
Termination of pregnancy 1 4
aAmong 79 respondents who had heard of misoprostol, data missing for one
pharmacy worker
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though continued professional development activities
[33]. In Senegal both public and private healthcare
providers (midwives, nurses and physicians) procure
medications from pharmacies. As well as being asked to
sell misoprostol, 15% of pharmacy workers who had heard
of the medication reported receiving requests from health
professionals for information about it, further highlighting
the importance of the pharmacist’s role and suggesting a
lack of knowledge about misoprostol among other health
professionals.
Oxytocin is the standard treatment for PPH, however
lack of skilled health providers, lack of transportation
and the medications’ need for refrigeration mean that it
is often not accessible to women in Senegal, particularly
in rural areas [13]. A recent trial in a rural area of
Senegal found misoprostol administered by auxiliary
midwives for PPH prevention both as effective as oxyto-
cin and feasible to use [13, 15]. Similarly, misoprostol
presents an opportunity for increased access to PAC in
Senegal: a 2012 survey found that many poor and rural
women don’t receive treatment for complications of
abortion [18]. The survey found that some health posts
(lowest level of nurse or midwife staffed public health
facility) in rural areas of the country were not equipped
to provide PAC but also noted that fear of criminal
charges and stigma may inhibit access to existing services
[18]. Unlike surgical PAC (manual or electric vacuum
aspiration or dilation and curettage), misoprostol requires
no surgical skills or equipment to administer making it
feasible to scale up in resource scarce settings [34]. How-
ever, there is limited availability of misoprostol in facilities
offering maternity services in Senegal [14] which may be
due to lack of awareness of its reproductive health uses
and limited supply of the drug.
Making misoprostol and information about its uses
widely available in Senegal is important for increasing
availability and quality of care for PAC and PPH. Phar-
macies can increase awareness of and access to miso-
prostol and can support its correct use however the
findings from this study demonstrate that these potential
benefits were not being realised. Since this survey was
conducted, in-service training and distribution of training
materials for pharmacists and prescribers on misoprostol
have been initiated in Senegal. Such interventions have
the potential to address the knowledge gaps identified
among these key groups. The rationale for increasing
access to misoprostol must be highlighted to ensure that
pharmacy workers recognise the contribution they can
have to reducing maternal mortality in the country.
One of the reasons pharmacy workers gave for not
stocking misoprostol was that they were unwilling to
stock an abortifacient. This may be due to objection to
abortion as reported in other countries [35]. In Senegal,
in cases of conscientious objection, pharmacists are
required to refer the client to another pharmacist or
healthcare provider. Other reasons for this unwillingness
to stock misoprostol could be lack of knowledge of the
product’s registration status and of its legal indications.
Wide dissemination of the EML could help de-stigmatise
the product and fully inform providers and pharmacist
workers of its life-saving properties for women experien-
cing PPH or in need of PAC [6]. In addition to these
actions, further research is required to better understand
the knowledge, attitudes and practice of health providers
towards misoprostol and to identify barriers that could
explain the low levels of prescription of the product.
A strength of this study is the unusually high participa-
tion rate despite the lack of financial incentive. It is likely
that the endorsement from the Order of Pharmacists, the
anonymous nature of the interviews and the explanation
by interviewers about the importance of the study played
a role in motivating pharmacy workers to take part. The
study has a number of limitations. 1) The study was lim-
ited to Dakar where transport links are good, and add-
itional research will be needed to assess misoprostol
knowledge and provision in other regions of Senegal. 2) It
is not clear whether the practice of respondents relate only
to individual practice or to a pharmacy-wide policy. 3)
Reporting on misoprostol sales and demand for misopros-
tol medications and information may have been subject to
recall bias. Respondents were asked to report on their
current practices however misoprostol may be a slow-
moving product which could make recall more difficult. 4)
Some of the findings may have been subject to reporting
bias i.e. respondents may have given answers that they
believe are politically correct and/or legally safe. More
than one third of pharmacists reported knowing that mi-
soprostol could be used for abortion and may therefore
have been hesitant to report stocking or selling it. Under-
reporting of abortion practices in restrictive countries is
known to be high due to fear of prosecution or stigma
[36–38]. In this survey, a number of behaviours may be
underreported including off-label provision, provision to
adolescents, provision for termination of pregnancy (abor-
tion is legal in very few circumstances and pharmacists
are not legally allowed to provide them) and provision for
PAC (which many perceive to be illegal). It is also possible
that provision to married clients and for gastric ulcer are
over reported. Further exploration is needed into the pos-
sibility that awareness of the link between misoprostol
and abortion is inhibiting pharmacy worker’s willingness
to stock and sell the product. Research methodologies
such as mystery clients, which minimize pharmacy
workers’ self-reporting bias, could be used to explore
provision practices further. In-depth interviews could also
be used to gain deeper understanding of pharmacy
workers’ views about the use of misoprostol as an abortifa-
cient and whether stigma affects provision practices.
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Conclusions
There is an urgent need to boost access to misoprostol
in Senegal as a strategy for increasing availability and
quality of care for PAC and PPH. Educating pharmacists
and pharmacy workers about misoprostol, its indications
for use and the correct dosages for each indication,
could help efforts to improve access to this important
reproductive health commodity in Senegal. Pharmacies
are a key component of the supply chain of medications
and their role in the scale-up of misoprostol must be
clarified promptly.
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